Effects of Type 2 Diabetes on Brain Structure and Cognitive Function: African American–Diabetes Heart Study MIND

References

1. 1.↵
   2. Wild S,
   3. Roglic G,
   4. Green A, et al

   . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53

   Abstract/FREE Full Text
2. 2.↵
   2. Simić I,
   3. Pecin I,
   4. Tedeschi-Reiner E, et al

   . Risk factors for microvascular atherosclerotic changes in patients with type 2 diabetes mellitus. Coll Antropol 2013;37:783–87

   PubMed
3. 3.↵
   2. Biessels GJ

   . Cerebral complications of diabetes: clinical findings and pathogenetic mechanisms. Neth J Med 1999;54:35–45

   CrossRefPubMedWeb of Science
4. 4.↵
   2. van Harten B,
   3. de Leeuw FE,
   4. Weinstein HC, et al

   . Brain imaging in patients with diabetes: a systematic review. Diabetes Care 2006;29:2539–48

   FREE Full Text
5. 5.↵
   2. van Elderen SG,
   3. de Roos A,
   4. de Craen AJ, et al

   . Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 2010;75:997–1002

   Abstract/FREE Full Text
6. 6.↵
   2. Moran C,
   3. Phan TG,
   4. Chen J, et al

   . Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care 2013;36:4036–42

   Abstract/FREE Full Text
7. 7.↵
   2. Vagelatos NT,
   3. Eslick GD

   . Type 2 diabetes as a risk factor for Alzheimer's disease: the confounders, interactions, and neuropathology associated with this relationship. Epidemiol Rev 2013;35:152–60

   Abstract/FREE Full Text
8. 8.↵
   2. Ryan JP,
   3. Fine DF,
   4. Rosano C

   . Type 2 diabetes and cognitive impairment: contributions from neuroimaging. J Geriatr Psychiatry Neurol 2014;27:47–55

   Abstract/FREE Full Text
9. 9.↵
   2. Sato N,
   3. Morishita R

   . Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci 2013;5:64

   PubMed
10. 10.↵
    2. Peek ME,
    3. Cargill A,
    4. Huang ES

    . Diabetes health disparities: a systematic review of health care interventions. Med Care Res Rev 2007;64(5 suppl):101S–56S

    Abstract/FREE Full Text
11. 11.↵
    2. Divers J,
    3. Hugenschmidt C,
    4. Sink KM, et al

    . Cerebral white matter hyperintensity in African Americans and European Americans with type 2 diabetes. J Stroke Cerebrovasc Dis 2013;22:e46–52

    CrossRefPubMed
12. 12.↵
    2. Thabit H,
    3. Kyaw Tun T,
    4. McDermott J, et al

    . Executive function and diabetes mellitus: a stone left unturned? Curr Diabetes Rev 2012;8:109–15

    CrossRefPubMed
13. 13.↵
    2. Qiu C,
    3. Sigurdsson S,
    4. Zhang Q, et al

    . Diabetes, markers of brain pathology, and cognitive cognition: the age, gene/environment susceptibility—Reykjavik study. Ann Neurol 2014;75:138–46

    CrossRefPubMed
14. 14.↵
    2. Teng EL,
    3. Chui HC

    . The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry 1987;48:314–18

    PubMedWeb of Science
15. 15.↵
    2. Grace J,
    3. Nadler JD,
    4. White DA, et al

    . Folstein vs modified Mini-Mental State Examination in geriatric stroke: stability, validity, and screening utility. Arch Neurol 1995;52:477–84

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Nasreddine ZS,
    3. Phillips NA,
    4. Bedirian V, et al

    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–99

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Strauss E,
    3. Sherman S,
    4. Spreen O

    . A Compendium of Neuropsychological 661 Tests: Administration, Norms, and Commentary. 3rd ed. New York: Oxford University Press; 2006
18. 18.↵
    2. Duff K,
    3. Schoenberg MR,
    4. Scott JG, et al

    . The relationship between executive functioning and verbal and visual learning and memory. Arch Clin Neuropsychol 2005;20:111–22

    Abstract/FREE Full Text
19. 19.↵
    2. Wechsler D

    . Wechsler Adult Intelligence Scale. 3rd ed. San Antonio: Psychological Corp; 1997
20. 20.↵
    2. Hoyer WJ,
    3. Stawski RS,
    4. Wasylyshyn C, et al

    . Adult age and digit symbol substitution performance: a meta-analysis. Psychol Aging 2004;19:211–14

    CrossRefPubMed
21. 21.↵
    2. Rosano C,
    3. Simonsick EM,
    4. Harris TB, et al

    . Association between physical and cognitive function in healthy elderly: the health, aging and body composition study. Neuroepidemiology 2005;24:8–14

    CrossRefPubMedWeb of Science
22. 22.↵
    2. MacLeod CM

    . Half a century of research on the Stroop effect: an integrative review. Psychol Bull 1991;109:163–203

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Houx PJ,
    3. Jolles J,
    4. Vreeling FW

    . Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res 1993;19:209–24

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Klein M,
    3. Ponds RW,
    4. Houx PJ, et al

    . Effect of test duration on age-related differences in Stroop interference. J Clin Exp Neuropsychol 1997;19:77–82

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Van der Elst W,
    3. Molenberghs G,
    4. Van Boxtel MP, et al

    . Establishing normative data for repeated cognitive assessment: a comparison of different statistical methods. Behav Res Methods 2013;45:1073–86

    CrossRefPubMed
26. 26.↵
    2. Reis JP,
    3. Launer LJ,
    4. Terry JG, et al

    . Subclinical atherosclerotic calcification and cognitive functioning in middle-aged adults: the CARDIA study. Atherosclerosis 2013;231:72–77

    CrossRefPubMed
27. 27.↵
    2. Radloff LS

    . The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401

    Abstract
28. 28.↵
    2. Gilbar O,
    3. Ben-Zur H

    . Adult Israeli community norms for the Brief Symptom Inventory (BSI). Int J Stress Manage 2002;9:1–10

    CrossRef
29. 29.↵
    2. Ashburner J,
    3. Friston KJ

    . Voxel-based morphometry: the methods. Neuroimage 2000;11:805–21

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Schmidt P,
    3. Gaser C,
    4. Arsic M, et al

    . An automated tool for detection of FLAIR-hyperintense white-matter lesions in multiple sclerosis. Neuroimage 2012;59:3774–83

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Maldjian JA,
    3. Whitlow CT,
    4. Saha BN, et al

    . Automated white matter total lesion volume segmentation in diabetes. AJNR Am J Neuroradiol 2013;34:2265–70

    Abstract/FREE Full Text
32. 32.↵
    2. Jovicich J,
    3. Czanner S,
    4. Han X, et al

    . MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 2009;46:177–92

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Han X,
    3. Jovicich J,
    4. Salat D, et al

    . Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006;32:180–94

    CrossRefPubMedWeb of Science
34. 34.↵
    2. Aggarwal NT,
    3. Wilson RS,
    4. Bienias JL, et al

    . The association of magnetic resonance imaging measures with cognitive function in a biracial population sample. Arch Neurol 2010;67:475–82

    CrossRefPubMedWeb of Science
35. 35.↵
    2. Brickman AM,
    3. Schupf N,
    4. Manly JJ, et al

    . Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. Arch Neurol 2008;65:1053–61

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Kumar R,
    3. Anstey KJ,
    4. Cherbuin N, et al

    . Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60- to 64-year-old community sample. Am J Geriatr Psychiatry 2008;16:989–98

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Biessels GJ,
    3. Koffeman A,
    4. Scheltens P

    . Diabetes and cognitive impairment: clinical diagnosis and brain imaging in patients attending a memory clinic. J Neurol 2006;253:477–82

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Schmidt R,
    3. Launer LJ,
    4. Nilsson LG, et al

    . Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) study. Diabetes 2004;53:687–92

    Abstract/FREE Full Text
39. 39.↵
    2. Manschot SM,
    3. Biessels GJ,
    4. de Valk H, et al

    . Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007;50:2388–97

    CrossRefPubMed
40. 40.↵
    2. Kumar A,
    3. Haroon E,
    4. Darwin C, et al

    . Gray matter prefrontal changes in type 2 diabetes detected using MRI. J Magn Reson Imaging 2008;27:14–19

    CrossRefPubMedWeb of Science
41. 41.↵
    2. de Bresser J,
    3. Tiehuis AM,
    4. van den Berg E, et al

    . Progression of cerebral atrophy and white matter hyperintensities in patients with type 2 diabetes. Diabetes Care 2010;33:1309–14

    Abstract/FREE Full Text
42. 42.↵
    2. Biessels GJ,
    3. Staekenborg S,
    4. Brunner E, et al

    . Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64–74

    CrossRefPubMedWeb of Science
43. 43.↵
    2. Biessels GJ,
    3. Deary IJ,
    4. Ryan CM

    . Cognition and diabetes: a lifespan perspective. Lancet Neurol 2008;7:184–90

    CrossRefPubMedWeb of Science
44. 44.↵
    2. Kloppenborg RP,
    3. van den Berg E,
    4. Kappelle LJ, et al

    . Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 2008;585:97–108

    CrossRefPubMedWeb of Science